This cluster groups 2 independently calculated changes: Cash & equivalents increased 130.5%; Operating cash flow increased 14.7%.
2 evidence-backed components· Pharmaceutical Preparations
RESEARCH SNAPSHOTQuoin Pharmaceuticals Ltd.'s latest supported as-filed period reports net income of -$5.4M. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Cash & equivalents increased 130.5%; Operating cash flow increased 14.7%.
2 evidence-backed componentsCurrent assets changed +37.2% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
QNRX · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001104659-26-106705SEC ↗4Sep 1, 2026Period Aug 31, 20260001104659-26-104405SEC ↗4Sep 1, 2026Period Aug 31, 20260001104659-26-104404SEC ↗4Sep 1, 2026Period Aug 31, 20260001104659-26-104403SEC ↗4Sep 1, 2026Period Aug 31, 20260001104659-26-104402SEC ↗4Aug 28, 2026Period Aug 27, 20260001104659-26-103376SEC ↗4Aug 28, 2026Period Aug 27, 20260001104659-26-103374SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 31, 2026Filed Sep 1, 2026 | Myers MichaelChief Executive Officer | Open Market PurchaseDirect | 20,490 | $5 | $99,991 | Form 4 ↗ |
| Aug 31, 2026Filed Sep 1, 2026 | Myers MichaelChief Executive Officer | Open Market PurchaseDirect | 10,245 | — | — | Form 4 ↗ |
| Aug 31, 2026Filed Sep 1, 2026 | Carter Denise P.Chief Operating Officer | Open Market PurchaseDirect | 20,490 | $5 | $99,991 | Form 4 ↗ |
| Aug 31, 2026Filed Sep 1, 2026 | Carter Denise P.Chief Operating Officer | Open Market PurchaseDirect | 10,245 | — | — | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Current liabilities changed +52.5% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Total assets changed +34.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Cash & equivalents changed +130.5% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Research & development changed +76.9% from the comparable as-filed period.
Working capital / assets changed -451 basis points from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Operating cash flow changed +14.7% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001104659-26-102917